OvaScience to Present at the Oppenheimer Healthcare Conference

Guía de Regalos

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that Company management will present
at the Oppenheimer 26th Annual Healthcare Conference on
Tuesday, December 8 at 3:20 pm ET at the Westin New York Grand Central
in New York City.

A live audio webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at www.ovascience.com.
A replay of the webcast will be archived on the OvaScience website for
two weeks following the presentation.

About OvaScience
OvaScience (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because we believe women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience has commenced a preceptorship program
with the OvaPrimeSM treatment, which could increase a woman’s
egg reserve, and is developing the OvaTureSM treatment, a
potential next-generation IVF treatment that could help a woman produce
healthy, young, fertilizable eggs without hormone injections. OvaScience
treatments are not available in the United States. For more information,
please visit www.ovascience.com
and www.augmenttreatment.com
and connect with us on Twitter
and Facebook.

Forward-Looking Statements
This press release includes
forward-looking statements about the Company’s plans for the AUGMENT
treatment and two fertility treatments in development. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including risks
related to: the possibility that international IVF clinics that we work
with may determine not to begin or continue providing the AUGMENT
treatment for commercial or other reasons; our expectation that the
AUGMENT treatment and OvaPrime treatment meet the requirements of a
class of products exempt from premarket review and approval under
applicable regulations in those countries where we have launched or plan
to introduce the AUGMENT treatment and plan to introduce the OvaPrime
treatment; the commercial ramp up of the AUGMENT treatment; the science
underlying our treatment and treatments in development (including the
AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our
ability to obtain regulatory approval where necessary for our potential
treatments; our ability to develop our potential treatments, including
the OvaPrime and OvaTure treatments, on the timelines we expect, if at
all; our ability to commercialize the AUGMENT treatment and our
potential treatments, including the OvaPrime treatment, on the timelines
we expect, if at all; as well as those risks more fully discussed in the
“Risk Factors” section of our most recently filed Quarterly Report on
Form 10-Q and/or Annual Report on Form 10-K. The forward-looking
statements contained in this press release reflect our current views
with respect to future events. We anticipate that subsequent events and
developments will cause our views to change. However, while we may elect
to update these forward-looking statements in the future, we
specifically disclaim any obligation to do so. These forward-looking
statements should not be relied upon as representing our view as of any
date subsequent to the date hereof.

###

Contacts

OvaScience
Cara Mayfield, 617-714-9638
Director, Corporate
Communications
cmayfield@ovascience.com
or
Michael
Devine, 212-453-2324
michael.devine@fleishman.com